dolasetron: Clinical Trials

2 trials of dolasetron, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 42Completed 2

Follow dolasetron: new trials by email Literature Review of dolasetron trials Research Report on dolasetron

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose - Chemotherapy-induced Nausea and Vomiting
Phase 4CompletedHelsinn Healthcare SA4142021-02-012025-12-02
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
Aprepitant, Aprepitant Placebo, Ondansetron - Nausea, Vomiting
Phase 4CompletedMerck Sharp & Dohme LLC4942012-12-122018-09-25

Conditions studied

Vomiting (2)  ·  Nausea (1)  ·  Neoplasms (1)

Sponsors

Helsinn Healthcare SA (1)  ·  Merck Sharp & Dohme LLC (1)

Countries

China (1)  ·  Czechia (1)  ·  Germany (1)  ·  Greece (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Alex Molasiotis, prof. (1)

Results publications

PMID 27826874